QNRX Quoin Pharmaceuticals Ltd.

NASDAQ
$3.36

Quoin Pharmaceuticals Ltd. (QNRX) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is a loss of $1.90 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -10.4% since its last earnings release on November 5, 2026.

Quoin Pharmaceuticals Beat Consensus Estimates
Thursday, November 5, 2026 · 8:30 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 8:30 AM ET
Earnings Whisper
-
vs ($1.90)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.66

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals is a specialty pharmaceutical company focused on rare and orphan diseases. Quoin Pharmaceuticals, formerly known as Cellect Biotechnology Ltd., is based in Tel Aviv.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Charts powered in part by Lightweight Charts™ by TradingView.